Position in SVTR
Snapshot 2026-10-25- Startup SignalsRankedof 2,341–
- Life SciencesRankedof 248
- AI for ScienceTop 50%
About
Perceptic, founded in 2025 in London, UK by former Palantir executives, uses AI agents to help pharmaceutical companies connect research, clinical, and operational data across drug discovery, clinical trial design, and asset evaluation.
Technology & BusinessWhat · How · Which stage
Research AreasLife SciencesMedicine & PharmaHighEvidence
2026-09-07四维复核：产业环节依据公司简介中的明确技术任务、研究对象、研发流程或交付方式调整；未把愿景性表述、内部平台或泛化“临床/患者”词直接当作证据。；2026-09-09能力—环节一致性复核：整合临床业务数据并用于临床数据分析
Source：Official site · Updated 2026-09-07 · View source
CapabilitiesClinical R&DOptimization & DecisionHighEvidence
2026-09-07四维复核：产业环节依据公司简介中的明确技术任务、研究对象、研发流程或交付方式调整；未把愿景性表述、内部平台或泛化“临床/患者”词直接当作证据。；2026-09-09能力—环节一致性复核：整合临床业务数据并用于临床数据分析
Source：Official site · Updated 2026-09-07 · View source
Subjects临床研究与真实世界数据药物与候选疗法HighEvidence
IT桔子公司画像明确词：临床数据、药物；映射为：临床研究与真实世界数据；药物与候选疗法
Updated 2026-09-10
R&D StagesClinical Development & RegistrationDisease Mechanisms & Target DiscoveryHighEvidence
2026-09-07复核：只按简介中的明确流程词判定，不由泛化“平台/临床/生产”直接触发；复核结果：科学发现与靶点识别；临床开发与转化；2026-09-09药物研发环节标准化：原“科学发现与靶点识别；临床开发与转化”映射为“疾病机制研究与靶点发现；临床开发与注册转化”
Source：Official site · Updated 2026-09-07 · View source
Business ModelOwn Products / R&D PipelineSoftware / SaaS / Research PlatformHighEvidence
2026-09-07四维复核：产业环节依据公司简介中的明确技术任务、研究对象、研发流程或交付方式调整；未把愿景性表述、内部平台或泛化“临床/患者”词直接当作证据。；2026-09-09能力—环节一致性复核：整合临床业务数据并用于临床数据分析
Source：Official site · Updated 2026-09-07 · View source
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 3
Founders / team· 3
Funding history
- 2026-05Seed$12M
Investors · Accel, Air Street Capital, Elder GullSource · fortune.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Perceptic
AI agents that connect research, clinical and operational data for pharma in drug discovery, trial design and asset evaluation
Seed · $12M · 2026-05
$12M
United States
BusinessLatest roundTotal raisedDate- Onepot
Small-molecule synthesis for drug discovery for biopharma companies (AI + automated synthesis)
Seed · $13M · 2025-11
$13M - Tahoe Therapeutics
Develops large-scale single-cell datasets to train AI models of human cells for drug discovery
Undisclosed · $30M · 2025-08
$30M - Layer Health
Uses AI to analyze unstructured data in patient records, helping providers and researchers with quality reporting and clinical research
Series A · $25M · 2025-03
$25M
China
BusinessLatest roundTotal raisedDate- Purui Intelligence
AI-driven platform for end-to-end clinical trial automation and results delivery.
Series A · $14M · 2026-06
$14M - Anew Labs
AI-driven drug discovery and new drug development platform
Undisclosed · $290M · 2026-09 · Valuation $1.5B
$290MValuation $1.5B - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials
Series D+ · $210M · 2025-03
$210M
Europe
BusinessLatest roundTotal raisedDate- Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M - Iomed
NLP-based data extraction from medical records, clinical trials and patient surveys
Series A · $11M · 2023-09
$11M - Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M
Other / unspecified
BusinessLatest roundTotal raisedDate- Reliant AI
Uses generative AI to help biopharma companies organize and analyze data for clinical trials or scientific publications
Seed · $11M · 2024-08
$11M - Sarborg
AI agents that help pharmaceutical companies optimize drug repurposing and clinical trial decisions
Seed · $10M · 2025-08
$10M - QuantHealth
Helps researchers maximize clinical trial success rates
Series A · $17M · 2024-01
$17M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
40 Life Sciences deals in the last 24 months · 19 at a nearby stage · 1 in Western Europe
Request intro →Y Combinator
38 Life Sciences deals in the last 24 months · 26 at a nearby stage · 3 in Western Europe
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 3 at a nearby stage · 3 in Western Europe
Request intro →GV
14 Life Sciences deals in the last 24 months · 3 at a nearby stage · 3 in Western Europe
Request intro →Alumni Ventures
12 Life Sciences deals in the last 24 months · 8 at a nearby stage · 1 in Western Europe
Request intro →Catalio Capital Management
9 Life Sciences deals in the last 24 months · 2 at a nearby stage · 1 in Western Europe
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.